What is the share price of Solara Active Pharma Sciences Ltd (SOLARA) today?
The share price of SOLARA as on 23rd June 2025 is ₹534.35. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Solara Active Pharma Sciences Ltd (SOLARA) share?
The past returns of Solara Active Pharma Sciences Ltd (SOLARA) share are- Past 1 week: 3.91%
- Past 1 month: 10.95%
- Past 3 months: 0.70%
- Past 6 months: -18.96%
- Past 1 year: 17.93%
- Past 3 years: 69.53%
- Past 5 years: -10.08%
What are the peers or stocks similar to Solara Active Pharma Sciences Ltd (SOLARA)?
The peers or stocks similar to Solara Active Pharma Sciences Ltd (SOLARA) include:What is the market cap of Solara Active Pharma Sciences Ltd (SOLARA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Solara Active Pharma Sciences Ltd (SOLARA) is ₹2390.13 Cr as of 23rd June 2025.What is the 52 week high and low of Solara Active Pharma Sciences Ltd (SOLARA) share?
The 52-week high of Solara Active Pharma Sciences Ltd (SOLARA) is ₹882.80 and the 52-week low is ₹442.80.What is the PE and PB ratio of Solara Active Pharma Sciences Ltd (SOLARA) stock?
The P/E (price-to-earnings) ratio of Solara Active Pharma Sciences Ltd (SOLARA) is 4426.16. The P/B (price-to-book) ratio is 2.55.Which sector does Solara Active Pharma Sciences Ltd (SOLARA) belong to?
Solara Active Pharma Sciences Ltd (SOLARA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Solara Active Pharma Sciences Ltd (SOLARA) shares?
You can directly buy Solara Active Pharma Sciences Ltd (SOLARA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Solara Active Pharma Sciences Ltd
SOLARA Share Price
534.350.83% (+4.40)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SOLARA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SOLARA Performance & Key Metrics
SOLARA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 4,426.16 | 2.55 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.51 | 6.52 | 0.85% |
0%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
SOLARA Company Profile
SSL Pharma Sciences is a manufacturer of pharmaceutical preparation
SUNPHARMA
PE Ratio
36.56
36.56
1Y Return
11.24%
11.24%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
22.97
22.97
1Y Return
0.35%
0.35%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.50
19.50
1Y Return
8.83%
8.83%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
56.09
56.09
1Y Return
11.44%
11.44%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.28
21.28
1Y Return
12.08%
12.08%
Buy Reco %
46.43
46.43
SOLARA Sentiment Analysis
SOLARA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SOLARA Stock Summary · May 2025
The company faced a challenging fiscal year, marked by flat growth and missed revenue targets, particularly in the competitive Ibuprofen market. However, management has implemented significant cost reductions, achieving a 22% decrease in operating costs, and is optimistic about future growth driven by a strategic shift towards higher-margin products. With a successful debt reduction plan, net debt is projected to improve significantly, enhancing financial health and enabling a focus on profitable growth. Regulatory compliance has bolstered operational credibility, and the management's commitment to optimizing working capital and enhancing margins positions the company for a more robust FY '26. Overall, while challenges remain, there is a clear path towards recovery and growth.
SOLARA Stock Growth Drivers
SOLARA Stock Growth Drivers
6Operational Resilience and Cost Management
The company has demonstrated operational resilience despite challenges in FY '24, particularly with the Ibuprofen
Margin Expansion and Financial Improvement
The company has successfully improved its gross margin from 37.8% in FY '24 to 51.5%
SOLARA Stock Challenges
SOLARA Stock Challenges
6Revenue and EBITDA Shortfalls
The company significantly missed its revenue and EBITDA guidance for FY '25, which has raised
Competitive Pressures in Ibuprofen Market
The ibuprofen franchise is facing significant competitive pressure due to excess capacity and new plants
SOLARA Forecast
SOLARA Forecasts
Price
Revenue
Earnings
SOLARA Share Price Forecast
SOLARA Share Price Forecast
2025
Current
₹534.35
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹534.35
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SOLARA Company Revenue Forecast
SOLARA Company Revenue Forecast
2025
Current
₹1.29
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.29
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
SOLARA Stock EPS (Earnings Per Share) Forecast
SOLARA Stock EPS (Earnings Per Share) Forecast
2025
Current
₹0.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹0.14
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
SOLARA
SOLARA
Income
Balance Sheet
Cash Flow
Annual Normal View
SOLARA Income Statement
SOLARA Income Statement
Annual Normal View
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 523.43 | 1,399.06 | 1,349.27 | 1,645.65 | 1,288.36 | 1,466.36 | 1,294.29 | 1,292.08 | 1,292.08 | |||||||||
Raw Materials | 274.29 | 738.62 | 653.03 | 726.57 | 912.64 | 781.78 | 765.75 | 1,077.48 | 1,077.48 | |||||||||
| Power & Fuel Cost | 31.41 | 79.35 | 77.68 | 85.42 | 93.70 | 108.10 | 122.56 | |||||||||||
| Employee Cost | 68.53 | 185.81 | 204.13 | 229.37 | 236.34 | 228.63 | 243.92 | |||||||||||
| Selling & Administrative Expenses | 22.66 | 64.48 | 69.23 | 73.77 | 74.60 | 66.93 | 70.53 | |||||||||||
| Operating & Other expenses | 67.23 | 105.29 | 58.24 | 115.88 | -125.42 | 124.49 | 371.51 | |||||||||||
EBITDA | 59.31 | 225.51 | 286.96 | 414.64 | 96.50 | 156.43 | -279.98 | 214.60 | 214.60 | |||||||||
| Depreciation/Amortization | 33.98 | 83.10 | 94.16 | 108.66 | 112.32 | 111.19 | 103.33 | 99.25 | 99.25 | |||||||||
| PBIT | 25.33 | 142.41 | 192.80 | 305.98 | -15.82 | 45.24 | -383.31 | 115.35 | 115.35 | |||||||||
| Interest & Other Items | 25.14 | 82.42 | 77.89 | 84.48 | 75.28 | 90.06 | 105.11 | 114.81 | 114.81 | |||||||||
| PBT | 0.19 | 59.99 | 114.91 | 221.50 | -91.10 | -44.82 | -488.42 | 0.54 | 0.54 | |||||||||
| Taxes & Other Items | -0.18 | 0.48 | 0.30 | 0.10 | -32.95 | -22.64 | 78.97 | 0.00 | — | |||||||||
| Net Income | 0.37 | 59.51 | 114.61 | 221.40 | -58.15 | -22.18 | -567.39 | 0.54 | 0.54 | |||||||||
| EPS | 0.14 | 21.74 | 40.14 | 65.00 | -14.90 | -5.68 | -145.27 | 0.14 | 0.14 | |||||||||
| DPS | 0.00 | 4.61 | 1.84 | 6.45 | 0.00 | 2.76 | 0.00 | 0.00 | 0.00 | |||||||||
| Payout ratio | 0.00 | 0.21 | 0.05 | 0.10 | 0.00 | — | 0.00 | 0.00 | 0.00 |
SOLARA Company Updates
SOLARA Stock Peers
SOLARA Past Performance & Peer Comparison
SOLARA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Solara Active Pharma Sciences Ltd | 4,426.16 | 2.55 | — |
| Sun Pharmaceutical Industries Ltd | 36.56 | 5.95 | 0.96% |
| Cipla Ltd | 22.97 | 4.52 | 1.07% |
| Dr Reddy's Laboratories Ltd | 19.50 | 3.90 | 0.61% |
SOLARA Stock Price Comparison
Compare SOLARA with any stock or ETFCompare SOLARA with any stock or ETF
SOLARA
SOLARA Holdings
SOLARA Shareholdings
SOLARA Promoter Holdings Trend
SOLARA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
SOLARA Institutional Holdings Trend
SOLARA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SOLARA Shareholding Pattern
SOLARA Shareholding Pattern
SOLARA Shareholding History
SOLARA Shareholding History
Foreign Institutions
Mutual Funds Invested in SOLARA
Mutual Funds Invested in SOLARA
No mutual funds holding trends are available
Top 4 Mutual Funds holding Solara Active Pharma Sciences Ltd
| Funds (Top 4) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8609% | Percentage of the fund’s portfolio invested in the stock 0.09% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 39/84 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.2995% | Percentage of the fund’s portfolio invested in the stock 0.66% | Change in the portfolio weight of the stock over the last 3 months 0.36% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/73 (+1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0009% | Percentage of the fund’s portfolio invested in the stock 0.12% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 75/109 (-10) |
Compare 3-month MF holding change on Screener
smallcases containing SOLARA stock
smallcases containing SOLARA stock
Looks like this stock is not in any smallcase yet.
SOLARA Events
SOLARA Events
SOLARA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SOLARA Dividend Trend
No dividend trend available
SOLARA Upcoming Dividends
SOLARA Upcoming Dividends
No upcoming dividends are available
SOLARA Past Dividends
SOLARA Past Dividends
Cash Dividend
Ex DateEx DateAug 18, 2021
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Aug 18, 2021
Cash Dividend
Ex DateEx DateNov 19, 2020
Interim
Interim | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Nov 19, 2020
Cash Dividend
Ex DateEx DateJul 28, 2020
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jul 28, 2020
Cash Dividend
Ex DateEx DateAug 6, 2019
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Aug 6, 2019
SOLARA Stock News & Opinions
SOLARA Stock News & Opinions
Articles & Videos
Earnings
Solara Active Pharma Sciences reports consolidated net loss of Rs 2.10 crore in the March 2025 quarter
Net Loss of Solara Active Pharma Sciences reported to Rs 2.10 crore in the quarter ended March 2025 as against net loss of Rs 255.34 crore during the previous quarter ended March 2024. Sales declined 8.82% to Rs 273.01 crore in the quarter ended March 2025 as against Rs 299.43 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 0.54 crore in the year ended March 2025 as against net loss of Rs 567.39 crore during the previous year ended March 2024. Sales declined 0.40% to Rs 1283.76 crore in the year ended March 2025 as against Rs 1288.92 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales273.01299.43 -9 1283.761288.92 0 OPM %16.623.26 -16.07-7.38 - PBDT22.20-19.23 LP 99.79-194.92 LP PBT-2.10-44.48 95 0.54-298.25 LP NP-2.10-255.34 99 0.54-567.39 LP Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Solara Active Pharma's Ambernath facility clears USFDA inspection
The Agency with their designated investigator inspected the facility from 5th to 9th May 2025. The inspection established that the site is in an 'Acceptable State of Compliance' with Zero Form 483 inspectional observations from US FDA. Commenting on the inspection outcome, Sandeep Rao, MD & CEO said, 'We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.' Solara Active Pharma Sciences is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, the company offers a basket of diversified, high-value commercial APIs and contract manufacturing services. The company reported consolidated net profit of Rs 8.09 crore in Q3 FY25 as compared with net loss of Rs 275.34 crore in Q3 FY24. Net sales increased 41.7% YoY to Rs 300.31 crore in Q3 FY25. The scrip rose 0.54% to end at Rs 502.80 on the BSE.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to conduct board meeting
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to convene board meeting
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 2 April 2025.Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to hold board meeting
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 26 March 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences to incorporate wholly owned subsidiary
Solara Active Pharma Sciences approved the incorporation of wholly owned subsidiary in relation to proposed demerger of the CRAMS and Polymers Business into an independent listed entity. Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Solara Active Pharma Sciences reports consolidated net profit of Rs 8.09 crore in the December 2024 quarter
Net profit of Solara Active Pharma Sciences reported to Rs 8.09 crore in the quarter ended December 2024 as against net loss of Rs 275.34 crore during the previous quarter ended December 2023. Sales rose 41.70% to Rs 300.31 crore in the quarter ended December 2024 as against Rs 211.94 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales300.31211.94 42 OPM %19.21-76.29 - PBDT32.63-186.61 LP PBT8.09-212.57 LP NP8.09-275.34 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Solara Active Pharma Sciences announces board meeting date
Solara Active Pharma Sciences will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Solara Active Pharma Sciences Ltd Surges 2.77%
Solara Active Pharma Sciences Ltd gained 2.77% today to trade at Rs 688. The BSE Healthcare index is up 0.18% to quote at 45033.49. The index is up 1.18 % over last one month. Among the other constituents of the index, Ami Organics Ltd increased 2.56% and Innova Captab Ltd added 2.53% on the day. The BSE Healthcare index went up 39.68 % over last one year compared to the 9.34% surge in benchmark SENSEX. Solara Active Pharma Sciences Ltd has lost 12.6% over last one month compared to 1.18% gain in BSE Healthcare index and 4.52% drop in the SENSEX. On the BSE, 30 shares were traded in the counter so far compared with average daily volumes of 13010 shares in the past one month. The stock hit a record high of Rs 885.95 on 02 Dec 2024. The stock hit a 52-week low of Rs 321.93 on 15 Feb 2024.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Solara Active Pharma Sciences reports consolidated net profit of Rs 8.01 crore in the September 2024 quarter
Net profit of Solara Active Pharma Sciences reported to Rs 8.01 crore in the quarter ended September 2024 as against net loss of Rs 17.16 crore during the previous quarter ended September 2023. Sales declined 18.41% to Rs 346.95 crore in the quarter ended September 2024 as against Rs 425.24 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales346.95425.24 -18 OPM %17.678.85 - PBDT33.3514.37 132 PBT8.01-11.84 LP NP8.01-17.16 LP Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -1.54%, vs industry avg of 9.02%
Over the last 5 years, market share decreased from 0.64% to 0.34%